HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

R B Warren Selected Research

Biological Therapy

10/2021Defining trajectories of response in patients with psoriasis treated with biologic therapies.
1/2021Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
7/2020Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.
4/2020Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
1/2020Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).
1/2020Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
12/2019A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis.
9/2019Safety of selective IL-23p19 inhibitors for the treatment of psoriasis.
1/2019Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study.
10/2018What's new in psoriasis treatment? An analysis of systematic reviews published in 2015.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


R B Warren Research Topics

Disease

77Psoriasis (Pustulosis Palmaris et Plantaris)
08/2022 - 11/2005
9Necrosis
01/2021 - 08/2009
7Infections
04/2021 - 02/2013
6Psoriatic Arthritis
01/2020 - 03/2012
3Skin Diseases (Skin Disease)
08/2020 - 02/2016
2Latent Tuberculosis
04/2021 - 11/2020
2Stroke (Strokes)
04/2020 - 04/2017
2Myocardial Infarction
04/2020 - 04/2017
2Autoimmune Diseases (Autoimmune Disease)
04/2013 - 03/2011
2Rheumatoid Arthritis
04/2013 - 02/2009
2Liver Cirrhosis (Hepatic Cirrhosis)
07/2011 - 08/2008
1Tuberculosis (Tuberculoses)
04/2021
1COVID-19
01/2021
1Atherosclerotic Plaque (Atheroma)
08/2020
1Non-alcoholic Fatty Liver Disease
08/2020
1Obesity
08/2020
1Metabolic Syndrome (Dysmetabolic Syndrome X)
08/2020
1Eczema
07/2020
1Eosinophilia
07/2020
1Atopic Dermatitis (Atopic Eczema)
07/2020
1Acute Coronary Syndrome
04/2020
1Unstable Angina
04/2020
1Neoplasms (Cancer)
01/2020
1Ankylosing Spondylitis
11/2018
1Autoimmune Thyroiditis (Lymphomatous Thyroiditis)
11/2016
1Type 2 Diabetes Mellitus (MODY)
11/2016
1Polyneuropathies (Polyneuropathy)
01/2014
1Hepatitis B
03/2013
1Genetic Predisposition to Disease (Genetic Predisposition)
03/2012
1Hepatitis C
08/2011
1Chronic Disease (Chronic Diseases)
12/2009

Drug/Important Bio-Agent (IBA)

15Biological ProductsIBA
10/2021 - 12/2009
13Ustekinumab (CNTO 1275)FDA Link
06/2022 - 01/2012
12Etanercept (Enbrel)FDA Link
01/2021 - 08/2009
10Methotrexate (Mexate)FDA LinkGeneric
04/2020 - 11/2005
10Adalimumab (Humira)FDA Link
04/2020 - 08/2009
9secukinumabIBA
01/2021 - 01/2017
6InterleukinsIBA
04/2021 - 02/2016
6Infliximab (Remicade)FDA Link
01/2019 - 04/2009
5risankizumabIBA
06/2022 - 09/2019
4Immunologic Factors (Immunomodulators)IBA
10/2021 - 12/2019
4tildrakizumabIBA
04/2021 - 09/2019
4Pharmaceutical PreparationsIBA
01/2020 - 02/2009
4ixekizumabIBA
01/2018 - 04/2017
3brodalumabIBA
08/2022 - 02/2021
3Certolizumab PegolFDA Link
12/2021 - 01/2021
3Interleukin-17 (Interleukin 17)IBA
04/2021 - 01/2020
3CytokinesIBA
04/2021 - 02/2016
3Interleukin-23 (Interleukin 23)IBA
04/2021 - 08/2020
3calcipotriene (calcipotriol)FDA LinkGeneric
02/2021 - 06/2015
3betamethasone-17,21-dipropionate (betamethasone dipropionate)FDA LinkGeneric
02/2021 - 06/2015
3GoldIBA
01/2021 - 03/2011
3Monoclonal AntibodiesIBA
01/2021 - 01/2019
3FumaratesIBA
10/2019 - 10/2018
2Biological FactorsIBA
01/2021 - 01/2021
2Prostaglandins AIBA
01/2020 - 01/2019
2Dimethyl FumarateIBA
10/2019 - 10/2018
2AcitretinFDA Link
01/2019 - 08/2011
2IGF-I-IGFBP-3 complexFDA Link
04/2016 - 03/2011
1Immunomodulating AgentsIBA
01/2021
1Immunoglobulin E (IgE)IBA
07/2020
1Immunoglobulin G (IgG)IBA
01/2020
1guselkumabIBA
09/2019
1Interleukin-23 Subunit p19IBA
09/2019
1Cyclosporine (Ciclosporin)FDA LinkGeneric
01/2019
1Tumor Necrosis Factor InhibitorsIBA
10/2018
1ElementsIBA
07/2017
1Betamethasone (Celestone)FDA Link
07/2017
1Interleukin-12 (IL 12)IBA
04/2017
1Toll-Like Receptor 4IBA
04/2016
1Toll-Like Receptors (Toll-Like Receptor)IBA
04/2016
1Proteins (Proteins, Gene)FDA Link
04/2016
1HLA-C Antigens (HLA-C)IBA
04/2015
1Genetic Markers (Genetic Marker)IBA
04/2013
1Biomarkers (Surrogate Marker)IBA
07/2011
1interleukin-21 (interleukin 21)IBA
03/2011
1Interleukin-2 (IL2)IBA
03/2011
1efalizumab (Raptiva)FDA Link
08/2009
1Alefacept (Amevive)FDA Link
08/2009
1Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA
02/2009
1RibonucleotidesIBA
02/2009
1gamma-Glutamyl Hydrolase (Carboxypeptidase G2)IBA
02/2009
1Hydroxymethyl and Formyl TransferasesIBA
02/2009
1DNA (Deoxyribonucleic Acid)IBA
02/2009
1Collagen Type III (Type III Collagen)IBA
08/2008
1Peptide FragmentsIBA
08/2008
1Protein Tyrosine PhosphatasesIBA
05/2008
1Folic Acid (Vitamin M)FDA LinkGeneric
11/2005

Therapy/Procedure

25Biological Therapy
10/2021 - 08/2008
20Therapeutics
04/2021 - 02/2009
1Contraindications
04/2021
1Aftercare (After-Treatment)
04/2021
1Chemoprevention
04/2021
1Duration of Therapy
01/2019
1Precision Medicine
10/2018
1Drug Tapering
05/2017
1Operative Surgical Procedures
01/2016
1Microbubbles
07/2011
1Complementary Therapies (Alternative Medicine)
10/2010